Viral Hepatitis Action Coalition Summit for the Elimination of Hepatitis B and Hepatitis C as Public Health Threats in the United States

Centers for Disease Control and Prevention
Tom Harkin Global Communications Center, Auditorium B
1600 Clifton Road
Atlanta, GA 30329
Thursday, April 27-28, 2017

April 27, 2017

8:00-8:45AM Continental Breakfast, Sign-In

8:45-9:00AM Welcome
Judith Monroe, M.D., F.A.A.F.P., President and Chief Executive Officer
CDC Foundation, Atlanta, GA
Jonathan Mermin, M.D., M.P.H., RADM, Director
National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC), Atlanta, GA

9:00-10:55AM A National Strategy for the Elimination of Hepatitis B and Hepatitis C

Co-Moderators:
Samuel So, M.B.B.S., F.A.C.S., Lui Hac Minh Professor and Director, Asian Liver Center, Stanford University School of Medicine, Stanford, CA
Ryan Clary, Executive Director, National Viral Hepatitis Roundtable, Washington, D.C.

World Health Organization: Strategic Framework and Global Goals
Marc Bulterys, M.D., M.P.H., Medical Officer, Global Hepatitis Programme, World Health Organization, Geneva, SZ

Definition of Elimination as a Public Health Threat
Jon Andrus, M.D., Adjoint Professor and Senior Investigator, Division of Vaccines and Immunization, Center for Global Health, Denver, CO

Questions & Discussion

A National Strategy for the Elimination of Hepatitis B and C
Gillian Buckley, Ph.D., M.P.H., Study Director, National Academies of Sciences, Engineering, and Medicine, Washington, D.C.

Meeting the Challenge of Viral Hepatitis Elimination for the Nation
Howard K. Koh, M.D., M.P.H., Harvey V. Fineberg Professor of the Practice of Public Health Leadership, Harvard T.H. Chan School of Public Health and Harvard Kennedy School, Boston, MA

Clinical Sponsor Perspective
Anna Lok, M.D., D.S.c., F.R.C.P., FAASLD., AGAF., President, American Association for the Study of Liver Diseases, Alexandria, VA

Community Sponsor Perspective
Ryan Clary, Executive Director, National Viral Hepatitis Roundtable, Washington, D.C.
HBV Patient Advocate Perspective
Sandy Andrada, B.A., Hepatitis B Patient Advocate, Asian Liver Center, Stanford, CA

HCV Patient Advocate Perspective
Ryan Clary on behalf of Alicia Suarez

Questions & Discussion

10:55-11:05AM
Break

11:05AM–12:30PM
Eliminating HCV Morbidity and Mortality
Moderator: Vincent Lo Re III, M.D., M.S.C.E., Associate Professor (Infectious Diseases) and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Hepatitis (B & C) Care in an Integrated Health System—Kaiser Permanente Mid-Atlantic States

Vulnerable Populations: Key Challenges and Interventions
Kendra Viner, Ph.D., M.P.H., Viral Hepatitis Program Manager, Philadelphia Department of Public Health, Philadelphia, PA

Questions & Discussion

Incarcerated Populations
Anne Spaulding, M.D., M.P.H., Associate Professor, Rollins School of Public Health, Emory University, Atlanta, GA

Questions & Discussion

Options for Financing HCV Elimination
Neeraj Sood, Ph.D., Professor of Public Policy, Sol Price School of Public Policy, University of Southern California, Los Angeles, CA

Questions & Discussion

12:30–1:30PM
Lunch (Provided)

1:30–3:00PM
Eliminating HCV Incidence
Moderator: Shruti Mehta, Ph.D., M.P.H., Professor and Deputy Chair Department of Epidemiology, John Hopkins Bloomberg School of Public Health Baltimore, MD

HCV Transmission Model for the United States
Peter Vickerman, D.Phil, Professor, Infectious Disease Modelling, University of Bristol, Bristol, UK

Questions & Discussion

HCV Prevention and Challenges for Persons Who Inject Drugs (PWID) in Urban Areas
Alain Litwin, M.D., Professor, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY

HCV Prevention and Challenges for PWID in Rural Areas
Kimberly Page, Ph.D., M.P.H., M.S., Professor and Chief of Epidemiology, Biostatistics & Preventive Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM

Questions & Discussion
Community Perspectives

Daniel Raymond, Deputy Director of Planning and Policy, Harm Reduction Coalition, New York City, NY

Access to Drug Treatment Services

Lisa Kaplowitz, M.D., M.S.H.A., Senior Medical Advisor, Substance Abuse and Mental Health Services Administration, Washington, D.C.

Questions & Discussion

3:00-3:15PM

Break

3:15-5:15PM

Model Viral Hepatitis Programs and Modeling

Moderator: Daniel Church, M.P.H., Senior Epidemiologist Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Boston, MA

Hepatitis C – Aiming for Elimination by 2030: Margaret Hellard, M.B.B.S., Ph.D., F.A.F.P.H.M., F.R.A.C.P., Deputy Director (Programs), Burnet Institute and Adjunct Professor, Monash University Melbourne, Australia

The Importance of Multipronged Approach

Questions & Discussion

Cherokee Nation Health Services Hepatitis C Elimination Program

Jorge Mera, M.D., F.A.C.P., Director, Infectious Diseases, Cherokee Nation Health Services

Questions & Discussion

National and State Models to Achieve the Goals of HCV Elimination

Homie Razavi, Ph.D., M.B.A., Managing Director, Center for Disease Analysis, Lafayette, CO

Questions & Discussion

Elimination Programs, Planning, and Modelling Panel

Hepatitis B and C Elimination in San Francisco: Collaborations, Strategies and Outcomes

Katie Burk, M.P.H., Viral Hepatitis Coordinator, Community Health Equity and Promotion Branch, San Francisco Department of Public Health, San Francisco, CA

New Mexico Elimination Planning

Sanjeev Arora, M.D., F.A.C.P., F.A.C.G., Director of Project ECHO and Professor, University of New Mexico Health Sciences Center, Albuquerque, NM

Community Efforts to Eliminate Hepatitis C in NYS

Colleen Flanigan, R.N., M.S., Director, Bureau of Hepatitis Health Care, New York Department of Health, Albany, NY

Louisiana Budget Allocator: Finding the funds to Cure HCV

DeAnn Gruber, Ph.D., Director, Bureau of Infectious Diseases, Office of Public Health, Louisiana Department of Health, New Orleans, LA

Questions & Discussion

5:15PM

Adjourn

5:30-7:30PM

Viral Hepatitis Action Coalition Award Ceremony & Reception

Judith Monroe, M.D., F.A.A.F.P., President and Chief Executive Officer, CDC Foundation [6:00-6:15PM Award Ceremony in atrium area outside of Auditorium B]
Friday, April 28, 2017

8:00-8:45AM  Continental Breakfast

9:00-10:30AM  Eliminating HBV Morbidity and Mortality

Moderator: Andrew Aronsohn, M.D., Associate Professor, Center for Liver Diseases, The University of Chicago Medicine, Chicago, IL


Questions & Discussion

A National Model to Achieve the Goals of Hepatitis B Elimination  Mehlika Toy, Ph.D., M.P.H., Basic Life Research Scientist, Department of Surgery, Stanford University, Stanford, CA

Community-Based Hepatitis B Project in Chicago  Karen Kim, M.D., M.S., Professor, Director of the Center for Asian Health Equity, The University of Chicago Medicine, Chicago, IL

Questions & Discussion

Eliminating HBV Morbidity and Mortality Panel

Integrating Hepatitis B into a Community-Based Health Care Setting in Seattle, WA  Grace Wang, M.D., M.P.H., F.A.A.F.P., Family Physician, Holly Park Medical and Dental Clinic, International Community Health Services, Seattle, WA

Outreach to African Migrant Communities  Nasra Giama, D.N.P., R.N., P.H.N., Clinical Assistant Professor, School of Nursing, University of Minnesota, Minneapolis, MN

Viral Hepatitis and Cancer Prevention  Durado Brooks, M.D., M.P.H., Managing Director, Cancer Control Intervention, American Cancer Society, Atlanta, GA

Questions & Discussion

10:30-10:45AM  Break

10:45-12:15PM  Eliminating HBV Incidence

Moderator: Samuel So, M.B.B.S., F.A.C.S., Lui Hac Minh Professor and Director, Asian Liver Center, Stanford University School of Medicine, Stanford, CA

Adult Hepatitis B Vaccination Coverage: Opportunities for Substantial Improvement  William Schaffner, M.D., Professor, Department of Health Policy and Division of Infectious Diseases, Vanderbilt University, Nashville, TN

Challenges of Providing HBV Vaccine through Health Departments  Carolyn Wester, M.D., M.P.H., Medical Director, Section HIV/AIDS, Tennessee Department of Health, Nashville, TN

Questions & Discussion

Model Urban Program: New York City  Julie Lazaroff, M.P.H., Coordinator, Perinatal Hepatitis B Prevention Unit, New York City Department of Health and Mental Hygiene, Long Island City, NY

Opportunities to Improve Hepatitis B Birth Dose Vaccination in the U.S.: A Community Perspective  Chari Cohen, Dr.P.H., M.P.H., Director of Public Health, Hepatitis B Foundation, Doylestown, PA

Questions & Discussion
Update: ACIP Recommendations for Hepatitis B Vaccination
Sarah Schillie, M.D., M.P.H., M.B.A., Medical Epidemiologist, Prevention Branch, Division of Viral Hepatitis (DVH), NCHHSTP, CDC, Atlanta, GA

Questions & Discussion

<table>
<thead>
<tr>
<th>12:15-1:15PM</th>
<th>Lunch (Provided)</th>
</tr>
</thead>
</table>

1:15-3:15PM
Hepatitis B and Hepatitis C Elimination: National Coordination, Tracking Progress, and Programs Targeting Special Populations

Co-Moderators:
John Ward, M.D., Director, DVH, NCHHSTP, CDC, Atlanta, GA
Judith Monroe, M.D., F.A.A.F.P., President and Chief Executive Officer, CDC Foundation, Atlanta, GA

Maximizing Impact Today: Working Toward a Brighter Tomorrow
Richard Wolitski, Ph.D., Director, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services, Washington, D.C.

Questions & Discussion

Tracking Progress Toward Elimination Goals

Leveraging Assets and Opportunities To Eliminate HCV in Massachusetts
Liisa Randall, Ph.D., Bureau of Infectious Diseases and Laboratory Science, Massachusetts Department of Public Health, Boston, MA

Tracking National Progress
Scott Holmberg M.D., M.P.H., Chief, Epidemiology and Surveillance Branch, DVH, NCHHSTP, CDC, Atlanta, GA

Performance Monitoring and Evaluation
Claudia Vellozzi, M.D., M.P.H., Chief, Prevention Branch, DVH, NCHHSTP, CDC, Atlanta, GA

Questions & Discussion

Programs Targeting Special Populations

Hepatitis C Elimination Efforts in Hemodialysis clinics
Ines Dahne-Steuber, Senior Vice President of Operational Excellence, Fresenius Kidney Care, Kennesaw, GA

Curing Hepatitis C in VA
Timothy Morgan, M.D., Director, National Hepatitis C Resource Center, Department of Veterans Affairs Medical Center, Long Beach, CA

Gilead Sciences – Support of Viral Hepatitis Elimination
Bruce Kreter, Pharm.D., Senior Director, HCV Medical Affairs, Gilead Sciences, San Francisco, CA

People Co-Infected with HIV
Harold Phillips, M.R.P., Director, Office of Training and Capacity Development, HIV AIDS Bureau, Health Resources and Services Administration, Rockville, MD

How Multi-Sector Partnerships can Advance Hepatitis C Elimination
Darshak Sanghavi, M.D., Chief Medical Officer and Senior Vice President, Translation, OptumLabs, Cambridge, MA

Questions & Discussion

3:15-3:30PM
Summary and Next Steps
David FitzSimons, B.S.c., Writer and Editor, Retired (World Health Organization), London, UK

3:30PM
Adjournment